Eletriptan Pfizer.

Paul J L M, Strijbos; Andrew A, Parsons; Anders, Fugelli

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2003

Data sources: Europe PubMed Central

Eletriptan Pfizer.

descriptionPublicationkeyboard_double_arrow_right Article 27 May 2003 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 3 (issn: 1472-4472,

Copyright policy )

Authors: Paul J L M, Strijbos; Andrew A, Parsons; Anders, Fugelli;

pmid: 12498013

Eletriptan Pfizer.

- Summary
- Subjects
- Metrics

Abstract

Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570]. Eletriptan pharmacology has also been evaluated in vitro in comparison with zolmitriptan (AstraZeneca plc) and naratriptan (GlaxoSmithKline plc) [290116].

Related Organizations

GlaxoSmithKline (United Kingdom)
United Kingdom

Keywords

Clinical Trials as Topic, Indoles, Pyrrolidines, Drug Industry, Animals, Humans, Tryptamines, Serotonin Receptor Agonists

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average